Biotech Currents

Biotech Currents

Home
Notes
Perspectives
BioCurrents Updates
Catalyst Table
Schedule
Archive
About

BioCurrents Updates

Clinical trial data from Ascendis (ASND), Tourmaline (TRML) push stocks higher
Data-driven rallies highlight potential in rare disease and cardiovascular care
 • 
Bill Langbein
ORR from Merus N.V.’s (NASDAQ:MRUS) H&N cancer drug triggers stock surge
The interim data from 43 evaluable patients revealed a 63% overall response rate
 • 
Bill Langbein
Portfolio Update: The floor plan takes shape for the Trump-RFK Biopharma agenda
Good news first.
 • 
Bill Langbein
1
Monogram (MGRM) holding gains after soaring following FDA nod for robotic surgical system
Shares of Monogram Technologies Inc. Soared
 • 
Bill Langbein
Protagonist (PTGX) hits on all key endpoints in PV trial
Protagonist Therapeutics (NASDAQ:PTGX) said on March 3, 2025, that its phase III Verify trial testing rusfertide in phlebotomy-dependent polycythemia…
 • 
Bill Langbein
Merck KGaA bids for SpringWorks (SWTX), Evolus (EOLS) receives FDA nod & Prothena (PRTA) struggles
Shares of SpringWorks Therapeutics, Inc.
 • 
Bill Langbein
Corcept (CORT) falls short in ALS while ‘unanticipated observation’ sent Keros (KROS) shares into freefall
Corcept Therapeutics Incorporated (NASDAQ: CORT) said after the markets closed on December 11 that its phase II trial evaluating its cortisol modulator…
 • 
Bill Langbein
Shares of New Amsterdam (NAMS) climb after phase III data exceeds expectations
Shares of New Amsterdam (NAMS) climb after phase III data exceeds expectations
 • 
Bill Langbein
Janux (JANX) Data Shines; Kura (KURA) Partners Leukemia Drug Ziftomenib on Belief in US Rights, Pipeline
Investors continue to reward new, potentially improved prostate cancer treatments as Janux Therapeutics, Inc.’s (NASDAQ:JANX) stock shot up ~55% on…
 • 
Bill Langbein
Novocure (NVCR), Inari (NARI) shares rise sharply on clinical data
Discontinuing coverage and exiting parts of its positions in NVCR and NARI.
 • 
Bill Langbein
Shares of Applied Thera (APLT) crash after CRL for primary drug
Applied Therapeutics, Inc. (Nasdaq: APLT) said it had received a complete response letter (CRL) from the FDA regarding its New Drug Application (NDA…
 • 
Bill Langbein
Perspective’s (CATX) radiopharma drug proves to be radioactive to investors
Perspective Therapeutics, Inc. (NYSE:CATX) put the best spin possible on phase I/II data for its radiopharmaceutical VMT-α-NET but at the end of the day…
 • 
Bill Langbein
© 2025 Bill Langbein
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture